19:41 , Nov 11, 2016 |  BC Week In Review  |  Company News

AdAlta, XL-protein deal

AdAlta and XL-protein partnered to develop and commercialize a long-acting version of AdAlta’s AD-114 to treat idiopathic pulmonary fibrosis (IPF). The partners will use XL-protein’s PASylation technology to increase the compound’s half-life and duration of...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

AdAlta completes IPO

AdAlta Ltd. (ASX:1AD), Bundoora, Australia   Business: Antibodies, Pulmonary   Date completed: 2016-08-12   Type: IPO   Raised: A$10 million ($7.7 million)   Shares: 40 million   Price: A$0.25   Shares after offering: 100 million   Underwriter: Patersons Securities   ...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers and...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Financial News

AdAlta proposes IPO

AdAlta Ltd., Bundoora, Australia   Business: Antibodies   Date announced: 2016-07-08   Type: IPO   To be raised: Up to A$10 million ($7.4 million)   Shares: TBD   Price: TBD   Note: AdAlta is seeking to list its shares on the Australian...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

AdAlta, Crossbeta Biosciences deal

Crossbeta and AdAlta partnered to use AdAlta's i-body technology with Crossbeta's stabilized beta-amyloid oligomers to develop oligomer-specific i-bodies for therapeutic and diagnostic applications in Alzheimer's disease (AD). AdAlta's i-bodies are the human equivalent of...